Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts… Read More
Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates- Novel Conditional Activation Platform Enabled by De Novo Protein Technology Preclinical Results Demonstrate Ability of NL-201 to Expand and… Read More
May 12, 2020 The Honourable Navdeep Bains, P.C., M.P. Minister of Innovation, Science and Industry C.D. Howe Building 235 Queen Street Ottawa, Ontario K1A 0H5 Dear Minister Bains; On behalf… Read More
Qu’s Site-Specific Immunomodulator (SSI) technology is recognized to be uniquely suited to address the problem the world is collectively grappling with – a novel emerging viral infection where there is… Read More
Vancouver, BC – May 14, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and… Read More
